Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Firefly Neuroscience (AIFF) EBITDA (2016 - 2025)

Firefly Neuroscience has reported EBITDA over the past 15 years, most recently at -$2.5 million for Q4 2025.

  • Quarterly results put EBITDA at -$2.5 million for Q4 2025, up 27.21% from a year ago — trailing twelve months through Dec 2025 was -$8.9 million (up 11.88% YoY), and the annual figure for FY2025 was -$8.9 million, up 11.92%.
  • EBITDA for Q4 2025 was -$2.5 million at Firefly Neuroscience, up from -$2.7 million in the prior quarter.
  • Over the last five years, EBITDA for AIFF hit a ceiling of $793000.0 in Q4 2023 and a floor of -$4.7 million in Q3 2022.
  • Median EBITDA over the past 5 years was -$1.3 million (2021), compared with a mean of -$1.5 million.
  • Biggest five-year swings in EBITDA: surged 314.36% in 2021 and later tumbled 4820.62% in 2022.
  • Firefly Neuroscience's EBITDA stood at -$1.3 million in 2021, then increased by 24.99% to -$1.0 million in 2022, then soared by 178.32% to $793000.0 in 2023, then plummeted by 533.29% to -$3.4 million in 2024, then increased by 27.21% to -$2.5 million in 2025.
  • The last three reported values for EBITDA were -$2.5 million (Q4 2025), -$2.7 million (Q3 2025), and -$1.6 million (Q2 2025) per Business Quant data.